Introduction

Rationale
Atrial fibrillation (AFib) affects an estimated 33 million individuals worldwide and is a major cause of stroke, heart failure, and death (1) . During the past decade, radiofrequency (RF) catheter ablation has evolved rapidly from an investigational procedure to its current status as a commonly used therapy for symptomatic AFib, after failure of at least one anti-arrhythmic drug (2, 3) . Recent advances in catheter design include the irrigated, contact-force (CF) sensing THERMOCOOL SMARTTOUCH® catheter from Biosense Webster, Inc. Real-time monitoring of CF is intended to promote uniform lesion formation and potentially reduce complications (4) . A handful of meta-analyses of CF catheters have been published, with inconsistent findings (4) (5) (6) . However, the Thermocool SmartTouch has not been studied separately for clinical endpoints (safety and efficacy) and procedure efficiency (procedure time, fluoroscopy use) compared to other ablation strategies without use of CF parameters.
Objectives
The objective of this literature review is to systematically assess evidence on the efficacy, safety, and efficiency of the Thermocool SmartTouch catheter for percutaneous ablation of paroxysmal or persistent AFib, compared with non-CF sensing catheters (any energy source) or to a SmartTouch catheter with operator blinded to CF data. A meta-analysis is planned, with results suitable for submission to regulatory agencies / notified bodies, and/or publication in a peer-reviewed journal. 
Methods
A search will be conducted in the setting of percutaneous catheter ablation of cardiac arrhythmia. Systematic review best practices will be followed to minimize bias (7) (8) (9) . Prospective study eligibility criteria, as outlined in this Protocol, will be applied, and a uniform data extraction template will be used in review of each study. Each included study will be appraised for quality using the Oxford Center for Evidence-Based Medicine (Oxford CEBM) Levels of Evidence (10).
Eligibility criteria
Human studies published between January 1, 2005 and August 1, 2017 (the search cut-off date) will be eligible for inclusion. Previous reviews have not yielded any studies prior to 2005 using the Thermocool SmartTouch catheter (the technology was not available) (4) (5) (6) . No restrictions will be placed on the language of publication, although the large majority of studies are expected to be in English. A broad search will be conducted in the setting of catheter ablation for atrial fibrillation, with full text retrieval and screening of potentially eligible studies. The intention is a comprehensive and up to date search of available evidence.
Information Sources
The National Library of Medicine's PubMed database (containing both MEDLINE and publishersupplied citations) will be the primary source for the electronic search. The Excerpta Medica (EMBASE®) database from Elsevier B.V., the Cochrane Library CENTRAL register, and manual reference checks will supplement the PubMed search. In addition, the database of ongoing and completed registered clinical trials at clinicaltrials.gov will be searched for any trials with relevant comparisons for which no matching publication was captured in the search.
Search Strategy
The PubMed web interface (www.ncbi.nlm.nih.gov) will be searched using the following terms, where "MeSH" indicates a MEDLINE Medical Subject Heading, and "tiab" indicates a keyword to be searched in the title and abstract: #1 AND #2, Limits: 2005-2017; NOT comments, editorials, reviews In addition to the PubMed search, the following sources will be searched:
 EMBASE, using either the Ovid interface or the EMBASE.com web interface, using terms similar to the PubMed search above. MeSH terms will be replaced with EMTREE indexing terms and/or keywords, as appropriate  Cochrane Library of systematic reviews (keywords "catheter ablation" or "atrial fibrillation") for all systematic reviews completed or updated 2010-2017; hand search of all completed reviews in Heart Review Group)
 Manual review of bibliographic references from prior systematic reviews and all accepted studies, to identify any potentially eligible studies missed during the electronic search
The search cut-off date for all of the above search components will be August 1, 2017. Studies made available online (Epub ahead of print) prior to being indexed in a journal will be eligible so long as the date of electronic publication is prior to the search cut-off date.
Study Records Data management
Search results will be downloaded from the PubMed website directly into a reference manager software (EndNote X7), which will be used to track studies through the selection process described below. Citations identified via each component of the search will be crosschecked to eliminate duplication. Separate publications reporting outcomes for the same or overlapping patient populations ("linked studies"), if found, will be grouped together during data extraction to avoid double-counting results for the same set of patients.
Selection Process
Studies will be eligible if they report outcomes of interest for at least 10 patients (in total) undergoing percutaneous catheter ablation of AFib with the Thermocool SmartTouch catheter compared to any non-CF catheter, or to a SmartTouch catheter with operator blinded to CF data. After the search is executed and downloaded, two levels of screening will be performed. Level I screening will be conducted on the title and abstract of each citation to identify potentially eligible studies, applying the inclusion and exclusion criteria outlined below. Level I screening will be performed by a single reviewer, with any questions resolved by consultation with a second reviewer. All potentially eligible studies will be sought in full text for further screening and extraction. At Level II screening, the full text will be evaluated by two independent reviewers for fit with inclusion and exclusion criteria, with questions or discrepancies resolved by consensus. The reason for exclusion will be noted for all articles rejected at Level I or II screening. A study attrition diagram (PRISMA format) will be prepared showing the number of citations included / excluded at each step. 
Data collection
A custom data extraction template will be designed for this review and pilot tested by two reviewers using a small sample of articles. The following data elements will be collected from each study, where available. Data will be extracted from each eligible study by one reviewer and verified back to the source article by a second reviewer. Discrepancies and differences in interpretation will be resolved through discussion, and if necessary, by consultation with a third analyst (team statistician or clinical expert). Outcomes data will be sought on an intent-to-treat basis preferentially; however, where this information is not available, data will be extracted as reported by authors. As-treated data may be analyzed if available. The final analyzable data set will be assembled in Microsoft Excel and quality checked prior to locking the data set for analysis by the project statistician.
Outcomes and Prioritization
Freedom from arrhythmia recurrence at 12 months follow-up after ablation, after single procedure, will be the primary outcome of interest. Between-group effect sizes as reported by the study authors will be used for meta-analysis, or, if between-group results are not available for an outcome of interest, effect sizes will be calculated using the patient numbers reported for each group. Patients lost to follow-up will be considered not to have procedure success.
Secondary endpoints will include complications and procedure efficiency (procedure, ablation and fluoroscopy duration / exposure).
Risk of Bias in Individual Studies
Each included study will be appraised for quality using the Oxford Center for Evidence-Based Medicine (Oxford CEBM) Levels of Evidence (Table 1) . Industry sponsorship will be captured for each included study, based on author disclosures or affiliation. 
Data Syntheses
Summary statistics (study counts and total Ns by intervention categories and key study characteristics) will be prepared using SAS version 9.2 or Microsoft Excel. Meta-analysis of primary and secondary outcomes (efficacy, safety and efficiency) will be performed where sufficient data exist. Meta-analysis will be performed using Comprehensive Meta-Analysis, Version 3. Graphics will be produced using Comprehensive Meta-Analysis, Microsoft Excel, or Tableau software.
A Statistical Analysis Plan (SAP) will be prepared in advance of any analysis of the study data and prior to preparation of the final data set. The SAP will detail methods and procedures for the statistical approach by type of outcome (binary, continuous, and time outcomes).
Study Heterogeneity
Heterogeneity across studies will be assessed. Potential sources of the heterogeneity will be further explored using sensitivity analysis, subgroup analysis, and meta-regression, as data permit. Pre-planned analyses will investigate: study design (randomized vs. non-randomized studies; randomized or non-randomized multivariable adjusted studies vs. non-randomized studies with no adjustment for patient characteristics), type of AFib (paroxysmal vs. persistent), and completeness of follow-up (% patients evaluated, of the total number beginning treatment).
Confidence in Cumulative Evidence
Funnel plots of the individual study outcomes will be prepared to evaluate the potential for publication bias or other systematic heterogeneity. Sensitivity analyses, subset analyses, and meta-regression will be performed as specified in the SAP to explore the robustness of results. 
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